全文获取类型
收费全文 | 13798篇 |
免费 | 668篇 |
国内免费 | 164篇 |
专业分类
耳鼻咽喉 | 127篇 |
儿科学 | 296篇 |
妇产科学 | 257篇 |
基础医学 | 1613篇 |
口腔科学 | 311篇 |
临床医学 | 1143篇 |
内科学 | 3837篇 |
皮肤病学 | 248篇 |
神经病学 | 1473篇 |
特种医学 | 445篇 |
外科学 | 1964篇 |
综合类 | 50篇 |
预防医学 | 653篇 |
眼科学 | 139篇 |
药学 | 825篇 |
中国医学 | 68篇 |
肿瘤学 | 1181篇 |
出版年
2023年 | 96篇 |
2022年 | 196篇 |
2021年 | 413篇 |
2020年 | 243篇 |
2019年 | 300篇 |
2018年 | 420篇 |
2017年 | 267篇 |
2016年 | 349篇 |
2015年 | 428篇 |
2014年 | 522篇 |
2013年 | 782篇 |
2012年 | 1127篇 |
2011年 | 1038篇 |
2010年 | 643篇 |
2009年 | 577篇 |
2008年 | 947篇 |
2007年 | 950篇 |
2006年 | 836篇 |
2005年 | 900篇 |
2004年 | 779篇 |
2003年 | 664篇 |
2002年 | 636篇 |
2001年 | 113篇 |
2000年 | 103篇 |
1999年 | 85篇 |
1998年 | 122篇 |
1997年 | 105篇 |
1996年 | 73篇 |
1995年 | 75篇 |
1994年 | 63篇 |
1993年 | 54篇 |
1992年 | 57篇 |
1991年 | 62篇 |
1990年 | 43篇 |
1989年 | 42篇 |
1988年 | 55篇 |
1987年 | 44篇 |
1986年 | 38篇 |
1985年 | 44篇 |
1984年 | 32篇 |
1983年 | 28篇 |
1982年 | 28篇 |
1981年 | 28篇 |
1980年 | 46篇 |
1979年 | 18篇 |
1978年 | 13篇 |
1977年 | 16篇 |
1976年 | 16篇 |
1975年 | 14篇 |
1974年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Federigo Sicuteri Maria Nicolodi Bruno Marcello Fusco Salvatore Orlando 《Headache》1991,31(9):577-581
Following tooth pulp extirpation, some subjects suffer from persistent pain which affects edentate sites in absence of any local pathology. As regards this peculiar pain, called phantom tooth pain (PTP), what is puzzling is the fact there is a low prevalence of PTP in a very large population showing identical conditions of tooth pulp extirpation. The present investigation indicates that PTP mainly affects migraine (M) and cluster headache (CH) sufferers, whereas it does not affect subjects who have a negative personal and family history for idiopathic headache (IH). These results circumscribe the presence of PTP to a specific section of the population. The present results, besides indicating that PTP may be the result of a peculiar neuronal predisposition relating to IH pathogenesis, suggests some practical therapeutic hints. In fact, successful anti- M and anti-CH prophylactic treatment greatly improve PTP syndrome. 相似文献
12.
Patients with Fabry disease on dialysis in the United States. 总被引:9,自引:0,他引:9
Ravi Thadhani Myles Wolf Michael L West Marcello Tonelli Robin Ruthazer Gregory M Pastores Gregorio T Obrador 《Kidney international》2002,61(1):249-255
BACKGROUND.: Fabry disease results from an X-linked deficiency of lysosomal alpha-galactosidase A and is a rare cause of end-stage renal disease. Little is known about the characteristics of patients with Fabry disease that initiate dialysis in the United States, although data from Europe suggests these individuals have a poor survival. METHODS.: Using the United States Renal Disease System database, we first studied in detail 42 Fabry patients who initiated dialysis between April 1995 (following the introduction of the new detailed HCFA 2728 form) and July 1998. To examine crude survival in a larger cohort, 95 Fabry patients were studied who initiated dialysis between 1985 and 1993, similar to the European Registry. Diabetic and non-diabetic controls matched by age, gender, race, year of dialysis initiation, and initial dialysis modality were examined for comparison. RESULTS.: During the years 1995 to 1998, the mean age of Fabry patients that initiated dialysis was 42 years, 83% were Caucasian, and 10% were African American. Despite the X-linked inheritance of Fabry disease, 12% of Fabry patients on dialysis were female. At initiation of dialysis mean serum albumin and creatinine were significantly higher and mean body mass index was significantly lower among Fabry patients, but mean glomerular filtration rate was similar to controls. Fabry patients tended to have a lower three-year survival compared to non-diabetic controls, but the results were not significantly different. In a larger cohort of Fabry patients who initiated dialysis between 1985 and 1993, the three-year survival of Fabry patients was significantly lower than non-diabetic controls: 63% (95% CI, 50 to 75%) versus 74% (95% CI, 67 to 80%; P=0.03). CONCLUSION.: End-stage renal disease is associated with significant morbidity and mortality among patients with Fabry disease. Recent evidence that progression of Fabry disease may be attenuated by enzyme replacement therapy necessitates increased awareness of Fabry disease and its comorbidities. 相似文献
13.
14.
Hemolytic anemia during pegylated IFN-alpha2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit. 总被引:1,自引:0,他引:1
Ivan Gentile Chiara Viola Laura Reynaud Francesco Borrelli Raimondo Cerini Rocco Ciampi Marcello Piazza Guglielmo Borgia 《Journal of interferon & cytokine research》2005,25(5):283-285
A 53-year-old woman admitted to our department for histologically proven chronic hepatitis C had previously been treated with pegylated interferon-alpha2b (PEG-IFN) plus ribavirin. Combination therapy had been withdrawn after 5 weeks because of severe anemia (hemoglobin 8.2 g/dl) despite a reduction in ribavirin dose. A second liver biopsy showed moderate chronic hepatitis with portoportal and portocentral bridges (Ishak score: grading 14/18, staging 4-5/6). Consequently, the patient was retreated with 1.5 microg/kg body weight weekly PEG-IFN and 1000 mg/day ribavirin. Ribavirin was withdrawn about 3 months later because of anemia. After 1 month of PEG-IFN alone, hemoglobin had decreased further to reach 7.9 g/dl; consequently IFN was stopped. An elevated reticulocyte count, indirect bilirubin concentration, and lactic dehydrogenase (LDH) concentration, and a positive direct Coombs test (IgG3, C3d also for panagglutinant irregular antibodies on eluate) led us to diagnose autoimmune hemolytic anemia (AHA). The patient received 1 mg/kg body weight/day prednisone, and all parameters normalized within 20 days. This is the first case of IFN-related AHA during PEG-IFN plus ribavirin therapy. Physicians should be aware that PEG-IFN can be the cause of AHA during a ribavirin-containing regimen for chronic hepatitis C. 相似文献
15.
Angelo Lipira David Limbrick Bruce Haughey Phillip Custer Michael R. Chicoine 《Skull base》2009,19(4):303-309
16.
17.
18.
Dr. Schön Dr. Angelo Mosso 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》1874,20(2):269-272
Ohne ZusammenfassungNachfolgendes schliesst sich an die Mittheilungen von Hering, Beiträge zur Physiologie, S. 310, an. 相似文献
19.
The results obtained in patients suffering from essential epistaxis in paediatric age using a peptide fraction derived from the enzymatic hydrolysis of bovine factor VIII (VUEFFE-Baldacci) are reported. Carbazochrome sodium sulphate was employed for comparison purposes. Vueffe is effective in reducing haemorrhagic episodes without modifying the laboratory parameters investigated. 相似文献
20.
Angelo M. Carella Sandro Nati Paolo Carlier Daniela Pierluigi Domenico Giordano Angela Congiu Gino Santini Daniele Scarpati Salvina Barra Renzo Corvo Vito Vitale Maria R. Raffo Raffaella Cerri Marco Risso Mauro Spriano Renato Vimercati Ester Pungolino Andrea Bacigalupo Eugenio Damasio 《Leukemia & lymphoma》1991,5(1):43-47
Forty consecutive adult patients under the age of 50 with acute non-lymphoblastic leukemia (ANLL) in first complete remission, underwent autologous bone marrow transplantation (ABMT) between March 1984 and April 1990. The conditioning regimen employed included cyclophosphamide and total body irradiation, followed by the administration of unpurged ABMT. The median time from diagnosis to transplant was 7 months (3-15 months), and the median time from complete remission to ABMT was 4 months (range 3-9 months). Twenty-two (51%) patients remain in complete remission 6-81 months (median 24 months) after ABMT.
The causes of death were, recurrent leukemia (11 patients), parenchymal toxicities such as acute respiratory distress syndrome and veno-occlusive disease (3 patients), hemorrhage (2 patients) and infection (2 patients). Eleven patients relapsed after 3-12 months (median 5 months). This study has produced survival data comparable to those of other institutions employing TBI for either allo or autotransplants. 相似文献
The causes of death were, recurrent leukemia (11 patients), parenchymal toxicities such as acute respiratory distress syndrome and veno-occlusive disease (3 patients), hemorrhage (2 patients) and infection (2 patients). Eleven patients relapsed after 3-12 months (median 5 months). This study has produced survival data comparable to those of other institutions employing TBI for either allo or autotransplants. 相似文献